JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M106458200 on October 22, 2001

J. Biol. Chem., Vol. 277, Issue 2, 1128-1138, January 11, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/2/1128    most recent
M106458200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hunt, M. C.
Right arrow Articles by Alexson, S. E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hunt, M. C.
Right arrow Articles by Alexson, S. E. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Characterization of an Acyl-CoA Thioesterase That Functions as a Major Regulator of Peroxisomal Lipid Metabolism*

Mary C. HuntDagger, Karianne Solaas§, B. Frode Kase, and Stefan E. H. Alexson

From the Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Karolinska Institutet, Huddinge University Hospital, SE-141 86 Stockholm, Sweden and the  Department of Pediatric Research, Rikshospitalet, NO-0027 Oslo, Norway

Received for publication, July 10, 2001, and in revised form, September 25, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Peroxisomes function in beta -oxidation of very long and long-chain fatty acids, dicarboxylic fatty acids, bile acid intermediates, prostaglandins, leukotrienes, thromboxanes, pristanic acid, and xenobiotic carboxylic acids. These lipids are mainly chain-shortened for excretion as the carboxylic acids or transported to mitochondria for further metabolism. Several of these carboxylic acids are slowly oxidized and may therefore sequester coenzyme A (CoASH). To prevent CoASH sequestration and to facilitate excretion of chain-shortened carboxylic acids, acyl-CoA thioesterases, which catalyze the hydrolysis of acyl-CoAs to the free acid and CoASH, may play important roles. Here we have cloned and characterized a peroxisomal acyl-CoA thioesterase from mouse, named PTE-2 (peroxisomal acyl-CoA thioesterase 2). PTE-2 is ubiquitously expressed and induced at mRNA level by treatment with the peroxisome proliferator WY-14,643 and fasting. Induction seen by these treatments was dependent on the peroxisome proliferator-activated receptor alpha . Recombinant PTE-2 showed a broad chain length specificity with acyl-CoAs from short- and medium-, to long-chain acyl-CoAs, and other substrates including trihydroxycoprostanoyl-CoA, hydroxymethylglutaryl-CoA, and branched chain acyl-CoAs, all of which are present in peroxisomes. Highest activities were found with the CoA esters of primary bile acids choloyl-CoA and chenodeoxycholoyl-CoA as substrates. PTE-2 activity is inhibited by free CoASH, suggesting that intraperoxisomal free CoASH levels regulate the activity of this enzyme. The acyl-CoA specificity of recombinant PTE-2 closely resembles that of purified mouse liver peroxisomes, suggesting that PTE-2 is the major acyl-CoA thioesterase in peroxisomes. Addition of recombinant PTE-2 to incubations containing isolated mouse liver peroxisomes strongly inhibited bile acid-CoA:amino acid N-acyltransferase activity, suggesting that this thioesterase can interfere with CoASH-dependent pathways. We propose that PTE-2 functions as a key regulator of peroxisomal lipid metabolism.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Peroxisomes are cellular organelles present in all eukaryotic cells. They play an indispensable role in the metabolism of a variety of lipids including very long-chain fatty acids, dicarboxylic fatty acids, bile acids, prostaglandins, leukotrienes, thromboxanes, pristanic acid, and xenobiotic fatty acids (for review, see Refs. 1 and 2). The peroxisomal beta -oxidation system contains two sets of enzymes, one of which is involved in the oxidation of branched chain fatty acids and intermediates in the hepatic bile acid biosynthetic pathway and consists of one or two branched-chain acyl-CoA oxidase(s), a D-specific bifunctional protein and the sterol carrier-like protein x (SCPx). The second pathway is involved in the oxidation of very long straight-chain fatty acids, CoA esters of prostaglandins, leukotrienes, and thromboxanes (prostanoids) and dicarboxylic acids. This system is composed of a straight-chain acyl-CoA oxidase, an L-specific bifunctional protein and straight-chain 3-ketoacyl-CoA thiolase. However, these two pathways are not mutually exclusive (1). All enzymes in this latter pathway are induced by peroxisome proliferators, whereas the enzymes in the former beta -oxidation pathway are not. Peroxisome proliferators are a group of structurally diverse compounds including hypolipidemic drugs, which induce peroxisome proliferation, hepatomegaly, and cause hepatocarcinogenesis in rodent liver. These peroxisome proliferators, together with free fatty acids, act as ligands for the peroxisome proliferator-activated receptor alpha  (PPARalpha )1 (3, 4). The PPARalpha is a nuclear receptor that plays a central role in fatty acid metabolism and induces the expression of many enzymes involved in peroxisomal and mitochondrial beta -oxidation and omega -oxidation of fatty acids. Targeted disruption of the PPARalpha gene in mouse has established a key role for this receptor as a mediator of lipid metabolism (5-8) and in the adaptive response to fasting (7-10).

Prior to transport into peroxisomes and beta -oxidation, all substrates must be activated to their CoA ester, which occurs at different cellular locations. Long-chain acyl-CoA synthetases are present in different subcellular membranes (11, 12) and long-chain acyl-CoA synthetase in the peroxisomal membrane activates very long and long-chain fatty acids and possibly branched-chain fatty acids to their CoA esters. Dicarboxylic fatty acids, prostanoids, and di- and trihydroxycoprostanic acid are activated to their CoA esters in the endoplasmic reticulum. These CoA esters are then transported into peroxisomes, possibly via ABC transporters. Peroxisomal beta -oxidation of very long and long-chain fatty acyl-CoAs results in chain-shortening of these esters, and the chain-shortened products can be transported as carnitine esters to mitochondria for further degradation. However, peroxisomes appear to have important roles in beta -oxidation of a number of xenobiotic carboxylic acids which may only be partially metabolized in peroxisomes (13, 14). The beta -oxidation of other CoA esters, such as prostanoids results in chain-shortening in peroxisomes, which are subsequently excreted in urine as the free carboxylic acid (for review, see Ref. 15). Similarly the beta -oxidation of dicarboxylic acids results in a chain-shortening in peroxisomes with the dicarboxylic acid being excreted in urine as the free acid or as glycine conjugates. Several of these carboxylic acids are only slowly beta -oxidized, implying that intraperoxisomal CoASH may be sequestered to such an extent that it becomes limiting. To maintain appropriate CoASH levels and to facilitate excretion of chain-shortened carboxylic acids, acyl-CoA thioesterases are likely to play important roles (for review, see Ref. 16). The hydrolysis of CoA esters to the free acids requires the presence of an acyl-CoA thioesterase, an enzyme that functions to hydrolyze CoA esters to the free acid and CoASH. To date, however, the specific thioesterase(s) active on CoA esters of prostanoids or dicarboxylic acids have not been identified.

Another important reaction that occurs in liver peroxisomes is the formation of bile acids. The primary bile acids, cholic acid and chenodeoxycholic acid, are formed by a number of enzymatic modifications of the cholesterol backbone by P-450 enzymes. The di- or trihydroxycoprostanoyl-CoA (DHCA-CoA or THCA-CoA) formed undergoes a final beta -oxidative cleavage of the side chain in peroxisomes with the release of propionyl-CoA, to form chenodeoxycholoyl-CoA and choloyl-CoA, respectively (17, 18). The peroxisomal bile acid-CoA:amino acid N-acyltransferase (BAAT) then catalyzes the conjugation of the CoA-activated bile acid to taurine or glycine prior to secretion from liver into bile. Recently, a multiorganellar bile acid-CoA thioesterase activity, which hydrolyzes the bile acid-CoA esters to free bile acids and CoASH, has been characterized in human liver peroxisomes (19, 20). This bile acid-CoA thioesterase activity described may compete with the BAAT enzyme for the bile acid-CoA substrate, thereby influencing intracellular levels of free and conjugated bile acids.

The existence of selective acyl-CoA thioesterases or a "broad range" acyl-CoA thioesterase could provide important control points in the oxidation of many peroxisomal substrates and to regulate intracellular levels of CoA esters and CoASH. This may be especially important during times of high beta -oxidation and fatty acid overload, to generate free CoASH necessary for fatty acid beta -oxidation to proceed. Acyl-CoA thioesterase activity has indeed been shown to be present in peroxisomes (21-24), and isolated rat brown adipose tissue peroxisomes contain acyl-CoA thioesterase(s) active on short- and medium-chain acyl-CoAs, which are inhibited by CoASH (23). Rat liver peroxisomes showed broad acyl-CoA thioesterase activity on C2-C22 acyl-CoAs, and one enzyme was partially purified, which was shown to be most active on myristoyl-CoA (24). To date, several peroxisomal acyl-CoA thioesterases have been cloned from yeast, mouse, and human. PTE-Ia and -Ib have been cloned from mouse, which belong to a novel family of Type I acyl-CoA thioesterases, with related enzymes also in cytosol and mitochondria (25). Acyl-CoA thioesterases have been identified in yeast and human peroxisomes, named PTE1 (26). The human homologue of PTE1 was previously identified as hACTEIII/hTE, a protein that interacted with and activated the HIV-1 Nef protein (27, 28). In the present study we have cloned the mouse homologue of PTE1/hACTEIII/hTE, which we have named mouse peroxisomal acyl-CoA thioesterase 2 (PTE-2). We have characterized this enzyme in detail, to examine its putative function in peroxisomal beta -oxidation. Characterization of PTE-2 suggests that it is a major thioesterase with an array of functions in peroxisomal lipid metabolism.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Chemicals-- [24-14C]Chenodeoxycholoyl-CoA and [24-14C]choloyl-CoA (specific activity 48.6 Ci/mol), trihydroxy-cholestanoyl-CoA, 2-methylstearoyl-CoA, and prostaglandin F2alpha -CoA were synthesized by the mixed anhydride procedure (29) and the former two CoA esters purified by high-pressure liquid chromatography (HPLC). [24-14C]Chenodeoxycholic acid and [24-14C]cholic acid were purchased from PerkinElmer Life Sciences. Optiprep and Maxidens were from Nycomed Pharma AS, Oslo, Norway. Taurine, chenodeoxycholic acid, cholic acid, all other acyl-CoAs, and coenzyme A were from Sigma. Prostaglandin F2alpha was from Cayman Chemical (Ann Arbor, MI).

Animals and Treatments-- Diurnal variation was investigated in adult male C57 BL/6 mice (B & K, Sollentuna, Sweden). The mice were maintained on a normal chow diet and sacrificed at the time points indicated. The dark periods were between 18.00 and 06.00 h. All other treatments were carried out on 10- to 12-week-old male wild-type or PPARalpha -null mice on a pure Sv/129 genetic background (derived from the original colony of mixed background mice) (5). These animals were housed in a temperature- and light-controlled environment. In fasting experiments, mice were maintained on a normal chow diet (R36 Lactamin, Vadstena, Sweden) prior to the start of the experiment and then transferred to new cages and fasted for 24 h. Alternatively mice were treated with 0.1% WY-14,643 (Calbiochem-Novabiochem International) in the diet for 1 week. All mice had access to water ad libitum. Animals were sacrificed by CO2 asphyxiation followed by cervical dislocation and weighed immediately. Tissues were then excised, weighed, and frozen in liquid nitrogen. For subcellular fractionation experiments, livers from untreated wild-type mice were homogenized directly after sacrifice.

Northern Blot Analysis-- Total RNA was isolated from mouse tissue samples using QuickPrep® Total RNA Extraction Kit (Amersham Biosciences Inc., Uppsala, Sweden), and Northern blot analysis was carried out as described previously (7). Blots were probed with the full-length cDNA for mouse PTE-2 or a probe for beta -actin and were exposed to x-ray film at -70 °C.

Identification of Human PTE-2 Gene-- Using human hACTEIII/hTE/hPTE1cDNA sequence (26-28) as search templates, a PAC clone containing ~86 kb of human genomic sequence was found to contain the gene encoding PTE-2. This human genomic sequence (GenBankTM accession number AL008726) was downloaded from NCBI (www.ncbi.nlm.nih.gov). The gene structure was compiled using Lasergene Software Package and 5' splice donor sites and 3' splice acceptor sites conformed to the general consensus sequences.

cDNA Cloning and Expression of PTE-2 in Escherichia coli-- The sequence for hACTEIII/hTE/hPTE1 (26-28) was used to search the mouse expressed sequence tag data base and several hits were obtained. The full-length cDNA sequence was compiled from overlapping expressed sequence tag sequences. The mPTE-2 cDNA was amplified using the following primers: 5'-CATATGTCAGCGCCAGAGGGTCTG-3' and 5'-CATATGCTATAGCTTACTCTCTGACACCAG-3'. Both primers were constructed with the addition of an NdeI site, indicated in bold. The full-length cDNA was amplified by reverse transcriptase-PCR using a template of clofibrate-treated mouse liver total RNA. PCR was performed in a PerkinElmer 2600 using the Gene-Amp XL PCR kit (PE Biosystems). Thermal cycling was performed at 98 °C for 10 min followed by 35 cycles of 94 °C for 1 min, 64 °C for 1 min, and 72 °C for 4 min. The resultant PCR product was cloned into the pCR-Script Amp (SK+) vector (Stratagene) and was subsequently sequenced.

The full-length cDNA for PTE-2 was excised from pCR-Script using NdeI restriction enzyme and cloned into the NdeI site in pET16b vector (Novagen Inc.). Sequence analysis was carried out to confirm the correct orientation. This plasmid was then used to transform BL21 (DES3)pLysS cells (Novagen Inc.). For expression of PTE-2, bacteria were cultured in 1 liter of Luria-Bertani medium at 37 °C, with addition of ampicillin (50 µg/ml) and chloramphenicol (34 µg/ml) until an A600 nm of about 0.6 was reached. Induction of protein expression was performed by addition of 1 mM isopropyl-1-thio-beta -D-galactopyranoside, and growth was continued overnight at room temperature. The bacteria were centrifuged at 8,000 × gmax for 10 min at 4 °C and the pellets were washed with 20 mM Tris, pH 8.0. The pellets were then frozen at -20 °C. Pellets were thawed and resuspended in 20 mM phosphate, 0.5 M sodium chloride, and 10 mM imidazole, pH 7.4, and sonicated 5 × 5 s, at 5-s intervals. The sonicated bacteria were then centrifuged at 36,000 × gmax for 1 h, and the supernatant was used for purification of PTE-2 on a HiTrapTM column (Amersham Biosciences, Inc.). Following equilibration of the column, the supernatant was applied, and the column was washed stepwise with 50, 100, 200, and 300 mM imidazole in 20 mM phosphate, 0.5 M sodium chloride, to remove contaminating proteins. The PTE-2 protein was eluted using 500 mM imidazole, 20 mM phosphate, 0.5 M sodium chloride and was subsequently used for acyl-CoA thioesterase activity measurements. The purity of PTE-2 was examined by SDS-PAGE analysis and Coomassie Brilliant Blue staining.

Localization of PTE-2 Using Green Fluorescent Fusion Protein and Cell Transfection Experiments-- Oligonucleotides were designed based on the sequence of the full-length cDNA for mouse PTE-2 for cloning as a fusion protein with green fluorescent protein (GFP), to examine targeting of the protein to peroxisomes. The full-length cDNA was amplified by One Step RNA PCR kit (avian myeloblastosis virus) (Takara Biomedicals) using the primers 5'-ATGTCAGCGCCAGAGGGTC-3' and 5'-CGAGCCAGGCATCTTTCAC-3' and was cloned into the pcDNA3.1/NT-GFP vector (Invitrogen) in-frame with the GFP at the N-terminal end. Sequence analysis was performed using Big Dye Terminator (ABI Prism, PE Biosystems) and was sequenced by Cybergene (Novum, Sweden).

Human skin fibroblasts from a control subject and a Zellweger patient were grown in Eagle's minimum essential medium (Sigma), supplemented with 10% fetal calf serum (Invitrogen) and 100 units of penicillin/100 µg of streptomycin in an atmosphere of 5% CO2. The Zellweger patient was a first-born, full-term female with muscular hypotonia, convulsions, and dysmorphic characteristics of Zellweger syndrome. The clinical diagnosis was verified by the accumulation of very long-chain fatty acids with a highly elevated C26/C22 ratio in cultured fibroblasts. Both control and Zellweger cells were grown overnight in 60-mm dishes on glass coverslips and were transfected with 8 µg of mPTE-2/GFP plasmid using the calcium phosphate method. Transfected cells were grown for 48 h, washed twice with PBS, and fixed in 3.7% paraformaldehyde in PBS for 20 min on ice. Cells were permeabilized in 0.5% Triton X-100 in PBS and rewashed in PBS. Following blocking in 2% BSA in PBS, 0.1% Tween 20 for 1 h, cells were incubated with rabbit green fluorescent protein antibody (Molecular Probes, Leiden, The Netherlands) for 1 h and washed four times with PBS, 2% BSA, and 0.1% Tween 20. Cells were then incubated with CY3-conjugated affinity pure donkey anti-rabbit IgG (Jackson ImmunoResearch) for 1 h. Cells were washed once with PBS, 0.1% Tween 20 (PBS-T) and nuclei were stained with Hoescht 33342 in PBS-T for 10 min. Cells were again washed twice in PBS-T and were mounted on glass slides using PPD (100 mg of p-phenylenediamine, 90% glycerol, and 10% PBS) and examined in Leica DM IRBE fluroescence microscope, using Hamamatsu C4742-95 camera and C4742-95 Twain Interface software.

Determination of Acyl-CoA Thioesterase Activity-- Acyl-CoA thioesterase activity was measured spectrophotometrically at 412 nm with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB). The medium contained 200 mM potassium chloride, 10 mM Hepes, and 0.05 mM DTNB, pH 7.4. An E412 = 13,600 m-1 cm-1 was used to calculate the activity. Since PTE-2 thioesterase activity was inhibited at substrate concentrations higher than 5-10 µM with acyl-CoAs longer than C10, BSA was added to a molar ratio of BSA/acyl-CoA of 1:4.5. The effect of CoASH, DTNB, and p-chloromercuribenzoic acid on enzyme activity was measured at 232 nm in phosphate buffered saline. The enzyme kinetics were calculated using Sigma Plot enzyme kinetics program.

Preparation and Characterization of Mouse Liver Subcellular Fractions-- Livers from wild-type and PPARalpha -null mice were homogenized as described previously (30), and bile acid-CoA thioesterase activity was measured as described in Ref. 19. Livers from untreated wild-type mice were fractionated as described (19). The peroxisome-enriched fraction was further fractionated using a 15-45% Optiprep gradient to obtain highly purified peroxisomes. Protein concentrations were determined according to Bradford (31).

BAAT Assay-- The possible interference of PTE-2 on peroxisomal BAAT activity was tested by addition of recombinant PTE-2 to incubations for BAAT activity. The reaction mixture contained the following: 50 mM potassium phosphate buffer, pH 8.0, 25 µM [24-14C]chenodeoxycholoyl-CoA, 20 mM taurine, 60 µg BSA, 2.27 µg of mouse liver peroxisomal protein, and 0.6 µg of purified recombinant PTE-2 in a total volume of 150 µl. Control samples were as above, but with inclusion of an equal volume HiTrapTM elution buffer (500 mM imidazole, 0.5 M sodium chloride, and 20 mM phosphate, pH 7.4) instead of PTE-2 protein. Following a 10-min preincubation at 37 °C, the reaction was started by addition of [24-14C]chenodeoxycholoyl-CoA and allowed to proceed for 1 h. The reaction was terminated by addition of 45 µl of 1 M KOH. After 30-min hydrolysis at 70 °C, the mixture was acidified using HCl and applied to a Sep-Pak C18-cartridge. The radioactive compounds were eluted with 2-propanol and methanol and analyzed by HPLC using a Beckman ODS 5 µ (4.6 mm × 25 cm) column with 20% 30 mM trifluoroacetic acid (adjusted to pH 2.9 with triethylamine) in methanol as mobile phase. The eluents were fractionated and assayed for 14C radioactivity by liquid scintillation counting.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PTE-2 Cloning and Sequence Analysis-- The cDNA isolated for PTE-2 encodes a protein of 320 amino acids, with a calculated molecular mass of 35,886 Da. Alignment of the deduced amino acid sequence for PTE-2 to the homologues in human (26-28), yeast (26), and E. coli (32) show the degree of sequence identity between the enzymes (Fig. 1). The mouse and human sequences show 85% sequence identity, the mouse and E. coli enzymes show 40% identity at amino acid level, while the yeast and mouse enzymes show 26% sequence identity. The amino acids elucidated to be involved in the active site catalytic triad (33), Asp-233 (D), Ser-255 (S), and Gln-305 (Q) are conserved between species, except for substitution of a threonine for serine in the E. coli enzyme. However this substitution should not alter the catalytic site capacity in view of the fact that both amino acids are polar.


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence alignment of acyl-CoA thioesterases from mouse, human, yeast, and E. coli. Alignment of mouse PTE-2, human PTE1 (26-28), yeast (Saccharomyces cerevisiae) PTE1 (26) and E. coli Thioesterase II (32) amino acid sequences was performed using the Clustal X method. Amino acids conserved between the thioesterase sequences are boxed in black. The active site aspartic acid (D) 233, serine/threonine (S/T) 255 and, glutamine (Q) 305 residues of the catalytic triad are all indicated with closed triangles.

Using bioinformatic techniques, we also identified the gene for human PTE-2. The gene was identified on human chromosome 20q12-q13 and comprised 6 exons, spaced by 5 introns, covering ~15.5-kb genomic DNA (Fig. 2). The 5' splice donor sites and 3' splice acceptor sites conformed to recognized exon/intron consensus sequences. Sequence analysis of the 5'-flanking region of the human PTE-2 identified a putative direct repeat 1 element of GGGTCAaAGGTCA, at -438 upstream of the ATG start methionine.


View larger version (7K):
[in this window]
[in a new window]
 
Fig. 2.   Gene organization for human PTE-2. The gene organization for human PTE-2 was determined as outlined under "Experimental Procedures." Individual exon sizes are shown (boxes), while intron sizes are shown underneath. A putative direct repeat 1 element is indicated at -438 upstream of the ATG start site.

PTE-2 Is Localized in Peroxisomes-- The mouse PTE-2 contains a well characterized consensus peroxisomal Type 1 targeting signal of -SKL (serine, lysine, leucine) at its C-terminal end, which has been shown to target proteins to peroxisomes (34). Previously, human PTE-2 has been shown to be localized in peroxisomes (26, 35), and to test whether mouse PTE-2 is peroxisomal, we cloned PTE-2 in-frame with GFP, which leaves the C-terminal -SKL sequence accessible. We transfected this vector into both control fibroblasts and fibroblasts from a Zellweger patient, which are unable to import peroxisomal matrix proteins. Using immunofluorescence microscopy for GFP detection, mPTE-2 showed a punctate pattern of expression in control fibroblasts, indicative of a peroxisomal localization (Fig. 3A). This localization was confirmed with a Tritc-labeled fluorescent secondary antibody to GFP (Fig. 3B). However, in Zellweger fibroblasts, transfection of mPTE-2 resulted in a diffuse GFP expression (Fig. 3D). The transfection of the Zellweger cells was confirmed using a Tritc-labeled fluorescent secondary antibody to GFP, which identified the transfected cells (Fig. 3E). Phase contrast microscopy is also shown in both cases (Fig. 3, C and F) as a control, indicating other untransfected cells. The strong staining present in the nucleus is Hoescht staining.


View larger version (105K):
[in this window]
[in a new window]
 
Fig. 3.   PTE-2 is a peroxisomal matrix protein. Human skin fibroblasts transfected with mPTE-2/GFP were processed for immunofluorescence microscopy by fixing and permeabilizing with 0.5% Triton X-100. The distribution of mPTE-2 was examined in control fibroblasts using GFP fluorescence (A) and Tritc-labeled anti-GFP antibody (B). The distribution of mPTE-2 in Zellweger fibroblasts was also carried out using GFP fluorescence (D) and Tritc-labeled anti-GFP antibody (E). Phase contrast microscopy is shown in C and F.

Recombinant Expression and Characterization of PTE-2-- The cloning of the cDNA encoding PTE-2 into the NdeI site of the pET16b vector results in expression of the PTE-2 as a His-tagged fusion protein, to allow for purification using affinity chromatography. Following purification of PTE-2 on a HiTrapTM column, the purified protein was detected as a single band of ~36 kDa in mass on SDS-PAGE gel stained with Coomassie Brilliant Blue (Fig. 4A). An antibody toward the human PTE1 (a kind gift from Jacob Jones) cross-reacted with the mouse PTE-2, confirming the correct protein (data not shown). The expressed protein was further analyzed by size-exclusion chromatography as described previously (36), using a Superdex HR 200 10/30 column operated in a SMART micropurification system (Amersham Biosciences Inc.). The recombinant PTE-2 protein eluted as an ~70-kDa protein, indicating a dimeric structure of the expressed PTE-2, similar to the crystal structure of the E. coli Thioesterase II enzyme (33).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4.   Kinetic characterization of recombinant mouse PTE-2. Expression of recombinant PTE-2 in pET16b vector was induced as described under "Experimental Procedures." A, recombinant PTE-2 was purified on a HiTrapTM column, and the purified protein was subjected to SDS-PAGE analysis and staining with Coomassie Brilliant Blue. Sizes of molecular weight markers are indicated. B, enzyme activity measurements were determined using purified PTE-2 as an enzyme source. Acyl-CoA thioesterase activity was measured with various concentrations of palmitoyl-CoA ± BSA at an albumin to substrate molar ratio of 1:4.5. C, acyl-CoA thioesterase activity on various CoA esters using purified PTE-2 as an enzyme source. Acyl-CoA thioesterase activity was measured with a 10 µM concentration of the indicated CoA ester, in the presence of BSA at a substrate to albumin molar ratio of 4.5:1 for CoA esters longer than C10. Cn, number of carbons; PGF2alpha , prostaglandin F2alpha -CoA, 2-CH3-C18, 2-methylstearoyl-CoA; Mal, malonyl-CoA; AcAc, acetoacetyl-CoA. D, inhibition of PTE-2 activity by CoASH. Acyl-CoA thioesterase activity was measured at 232 nm as described under "Experimental Procedures." The activity was measured using octanoyl-CoA as substrate, to avoid the required addition of BSA, which will strongly interfere at 232 nm when measuring activity with longer acyl-CoAs. CoASH was added to the enzyme assay at concentrations indicated.

Following initial enzyme activity characterization of the recombinant protein, it was evident that PTE-2 activity was inhibited at substrate concentrations >5-10 µM for long-chain acyl-CoAs. However, addition of BSA to an albumin/acyl-CoA ratio of 1:4.5 to the reaction prevented inhibition (Fig. 4B). Recombinant PTE-2 was analyzed for acyl-CoA thioesterase activity, which was determined at several concentrations with substrates of different chain lengths. Surprisingly, PTE-2 showed similar activity toward all acyl-CoAs tested ranging from C2 up to C20 straight-chain acyl-CoAs, together with activity toward long-chain unsaturated acyl-CoAs (Fig. 4C). Interestingly, PTE-2 also efficiently catalyzed the hydrolysis of CoA esters of bile acids, namely choloyl-CoA and chenodeoxycholoyl-CoA, at an ~3 times higher rate than with straight-chain acyl-CoAs, with THCA-CoA also being hydrolyzed at a high rate. The CoA esters of other substrates found in peroxisomes were also analyzed. PTE-2 hydrolyzed 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA), branched-chain CoA esters (4,8-dimethylnonanoyl-CoA and 2-methylstearoyl-CoA), the CoA ester of prostaglandin F2alpha , and acetoacetyl-CoA.

If PTE-2 is a major thioesterase in peroxisomes controlling CoASH levels, it is feasible that it may be directly regulated by CoASH. Indeed PTE-2 activity was strongly inhibited by CoASH with an IC50 of ~10-15 µM (Fig. 4D). PTE-2 activity was also inhibited by DTNB (IC50 approx  150 µM) and p-chloromercuribenzoic acid (IC50 approx  1 µM), two cysteine-reactive agents (data not shown); however, to date a cysteine involved in the active site catalysis has not been identified.

Calculation of the Vmax and Km values showed that the Km for medium- to long-chain acyl-CoAs was in the order of 1.4-6.7 µM, with short-chain acyl-CoAs ranging from 8 to 30 µM (Table I). The Km for bile acid-CoA esters was in the range of 9-15 µM. PTE-2 also hydrolyzed beta -oxidation intermediates such as 2-trans-decenoyl-CoA and 3-hydroxypalmitoyl-CoA, although at ~20% of the rates of decanoyl-CoA and palmitoyl-CoA. All Km values are rather low, strongly suggesting that all these CoA esters are substrates for PTE-2 in vivo.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Calculated Km and Vmax values for recombinant PTE-2
Thioesterase activity with different CoA esters were measured at different substrate concentrations. Activities were measured as described under "Experimental Procedures" using 0.3-1.2 µg of purified recombinant PTE-2. Km and Vmax values were calculated using Sigma Plot Enzyme Kinetic program. ND, not determined.

Recombinant PTE-2 and Isolated Mouse Liver Peroxisomes Show Strikingly Similar Acyl-CoA Thioesterase Substrate Specificities-- The acyl-CoA thioesterase chain length specificity was measured in isolated mouse peroxisomes (Fig. 5A). Activity was seen with straight-chain acyl-CoAs from chain length of C2 up to C20, together with very high activity toward bile acid-CoA esters, THCA-CoA, and branched-chain CoA esters. There was a striking similarity between the acyl-CoA chain length pattern for the recombinant PTE-2 and the chain length specificity in isolated peroxisomes (Fig. 5B). Superimposing the curves for the substrate specificities of isolated peroxisomes and that of PTE-2 showed that PTE-2 apparently catalyzes most of the activities seen in peroxisomes, with the only observable difference being the putative presence of an additional acyl-CoA thioesterase in peroxisomes, mainly catalyzing the hydrolysis of C12-C14-CoA. Comparison of the specific activities of recombinant PTE-2 and isolated peroxisomes indicates that PTE-2 constitutes about 1% of total peroxisomal protein.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Acyl-CoA thioesterase substrate specificity in purified peroxisomes and for recombinant PTE-2. A, acyl-CoA thioesterase activity measurements were determined in 2.27 µg of purified peroxisomes from wild-type mice treated with 0.1% WY-14,643 for 1 week, using a 25 µM concentration of various acyl-CoA esters. B, enzyme activity measurements were determined using purified PTE-2 as an enzyme source, using 0.3-1.2 µg of recombinant PTE-2 and 25 µM acyl-CoA as substrate.

PTE-2 Competes with Bile Acid-CoA:Amino Acid N-Acyltransferase for Bile Acid-CoA-- We examined the ability of recombinant PTE-2 to compete with BAAT for the bile acid-CoA substrate chenodeoxycholoyl-CoA. BAAT activity was measured in highly purified peroxisomes isolated from control mouse liver. Addition of recombinant PTE-2 caused an ~80% inhibition of BAAT activity (Table II). These data show that PTE-2 can compete with BAAT for the bile acid-CoA substrate in vitro. We have also tested the ability of recombinant mouse cytosolic acyl-CoA thioesterase I (mCTE-I) (37) to hydrolyze CA-CoA or CDCA-CoA. However, this enzyme showed no detectable activity with CA-CoA or CDCA-CoA, further emphasizing that the bile acid-CoA thioesterase activity of PTE-2 is specific (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Specific activity of bile acid-CoA:amino acid N-acyltransferase (BAAT) in purified peroxisomes from untreated wild-type mice
Addition of recombinant PTE-2 to the incubation mixture and detection of tauro-chenodeoxycholic acid formation was as described in "Experimental Procedures." All samples were measured in duplicate.

Choloyl-CoA Thioesterase Activity Is Induced in Mouse Liver in a PPARalpha -dependent Manner-- Since PTE-2 very efficiently hydrolyzes CoA esters of bile acids, and PPARalpha has been shown to be involved in bile acid biosynthesis (38), we investigated the possible regulation of bile acid-CoA thioesterase activity by feeding mice WY-14,643, a potent PPARalpha activator. In liver homogenates of wild-type mice, choloyl-CoA thioesterase activity was increased 3.5-fold following treatment with WY-14,643 (Fig. 6). However in PPARalpha -null mouse liver homogenates, this increase in choloyl-CoA thioesterase activity was not evident, showing that the WY-14,643-mediated induction of bile acid-CoA thioesterase activity in mouse liver was PPARalpha -dependent.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   Bile acid-CoA thioesterase activity is increased in mouse liver homogenates by WY-14,643 treatment. Specific choloyl-CoA thioesterase activity was measured as described under "Experimental Procedures" in homogenates from untreated PPARalpha wild-type (+/+) and null (-/-) mice and mice treated with 0.1% WY-14,643 (WY) for 1 week.

PTE-2 mRNA Expression Is PPARalpha -regulated-- In view of the fact that PTE-2 can hydrolyze bile acid-CoA esters, together with the fact that choloyl-CoA thioesterase activity was shown to be induced in a PPARalpha -dependent manner in mouse liver, we used the PPARalpha -null mouse model to examine regulation of the PTE-2 at mRNA level. The basal expression of PTE-2 in PPARalpha -null mice was approximately half that detected in wild-type animals. Treatment of mice with a WY-14,643-containing diet for 1 week resulted in a very strong (>10-fold) induction of PTE-2 mRNA (Fig. 7A, upper panel). However, this up-regulation was not evident in the PPARalpha -null mice also treated with WY-14,643, showing that the effect mediated on PTE-2 by peroxisome proliferators is dependent on the PPARalpha .


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7.   Northern blot analysis of PTE-2 mRNA expression in mouse liver. A, upper panel, groups of six PPARalpha -null mice (-/-) or age-matched wild-type mice (+/+) were fed 0.1% WY-14,643 for 1 week, while control animals had access to normal chow diet ad libitum. Mice were sacrificed, and total RNA was isolated from liver. Northern blot analysis was carried out on 20 µg of total RNA using alpha -32P-labeled cDNA probe for PTE-2 as described under "Experimental Procedures." A representative blot with two samples per group is shown together with the ethidium bromide staining of the blot with positions of the 28 and 18 S bands indicated. Lower panel, Northern blot analysis of mouse liver total RNA from control mice or mice fasted for 24 h. B, PTE-2 mRNA expression shows diurnal variation. C57 BL/6 mice were maintained on a normal chow diet ad libitum and were sacrificed at the time points indicated. The light period was between 06.00 and 18.00 and the dark period between 18.00 and 06.00. Northern blot analysis was carried out on 20 µg of total RNA using alpha -32P-labeled probes for PTE-2 and beta -actin. Filters were exposed to x-ray film, and signals were quantified using Image Master Software 3.0. The mean of PTE-2/actin mRNA ± range for two animals is shown. C, tissue expression of PTE-2 mRNA. Total RNA was isolated from various tissues of Sv129 male mice. Northern blot analysis was carried out on 20 µg of total RNA using alpha -32P-labeled cDNA probe for PTE-2 as described under "Experimental Procedures." Ethidium bromide (EtBr) staining of the gel shows even loading of samples.

The role of the PPARalpha in the fasting-mediated induction of several genes has also been shown (7-10, 38). We examined the effect of fasting on PTE-2 mRNA levels in the PPARalpha -null mouse model, which resulted in a significant increase in PTE-2 mRNA in liver (Fig. 7A, lower panel). However, this induction was not seen in the PPARalpha -null mice that were similarly treated.

PTE-2 Shows a Diurnal Regulation of Expression-- As PTE-2 is regulated by fasting and is therefore under nutritional regulation, we examined whether this enzyme could also be under a diurnal regulation. Mice were fed a normal chow diet and were sacrificed every 4th h commencing at 09.00 h. Quantitation of the mRNA signal showed that during the light period (between 06.00 and 18.00 h), when animals are less active, the mRNA levels were increased, thus indicating an induction by fasting (Fig. 7B). During the dark period, when feeding mainly takes place (between 18.00 and 06.00 h) the mRNA levels declined rapidly, indicating a rapid nutritional regulation in response to refeeding.

PTE-2 mRNA Is Ubiquitously Expressed-- The tissue expression of PTE-2 was examined using Northern blot analysis on several different tissues from mouse (Fig. 7C). PTE-2 was ubiquitously expressed as a 1.2-kb transcript in all tissues examined, which is similar to results obtained for expression in human tissues (27). Tissue expression was highest in kidney, liver, and testis, with weaker expression evident in heart and muscle. In testis a second transcript was evident at ~2 kb, which may be due to splicing events. PTE-2 is therefore widely expressed in tissues, similar to that of the peroxisomal beta -oxidation enzymes acyl-CoA oxidase, L-bifunctional enzyme and 3-ketoacyl-CoA thiolase (39).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study we have cloned and characterized the mouse peroxisomal acyl-CoA thioesterase 2, called PTE-2, which is localized in peroxisomes. This enzyme is the mouse homologue of human PTE1 (26), which was first identified by the yeast two-hybrid system as hACTEIII and hTE, a HIV-1 Nef-binding protein (27, 28). There is a lot of confusion regarding the nomenclature of acyl-CoA thioesterases, and based on a recent attempt to accomplish a more uniform terminology (16), we propose the name PTE-2 for this acyl-CoA thioesterase, as the nomenclature PTE-I has already been assigned to two enzymes that are members of a novel multigene family, with other members in mitochondria and cytosol (25) (Table III). However, the rule applied to the nomenclature of yeast enzymes states that they remain known by the name applied when they were first identified, therefore this enzyme will remain known as PTE1. A human PTE2 cloned as a putative peroxisomal enzyme (40) (Table III) shows 100% identity to human MTE-I (mitochondrial acyl-CoA thioesterase) without its N-terminal sequence. This MTE-I belongs to a novel family of acyl-CoA thioesterases in human, with localizations also in cytosol and peroxisomes.2

                              
View this table:
[in this window]
[in a new window]
 
Table III
Nomenclature for peroxisomal acyl-CoA thioesterases

The HIV-1 Nef, which interacts with the thioesterase PTE-2, is a cytosolic 27-kDa myristoylated protein that is required for high viral load and full pathological effect of HIV (41). It is thought that Nef activity triggers endocytosis of CD4 and major histocompatibility complex class-I molecules. Although the interaction of Nef with the acyl-CoA thioesterase is not fully understood, it has been shown that Nef contains sites critical for binding of the human thioesterase, which results in down-regulation of CD4 (35). The binding of Nef to the thioesterase also targets Nef to peroxisomes in vivo and increases thioesterase activity in vitro (27). It was also shown that abolishment of the interaction of the thioesterase with Nef resulted in impairment of Nef biological functions (42). It then became evident that although this thioesterase may have a putative function in the pathogenesis of HIV, the enzyme may also be involved in fatty acid metabolism. In 1999, Jones et al. (26) again characterized this enzyme in human, which they named PTE1, together with a yeast homologue, showing these proteins are targeted to the peroxisomal lumen. The yeast PTE1 identified showed regulation at mRNA level by growth on oleate. In yeast, beta -oxidation of fatty acids is confined only to peroxisomes, and growth of yeast on oleate as sole carbon source results in increased expression of peroxisomal enzymes and proliferation of peroxisomes. Disruption of PTE1 in yeast resulted in a loss of approximately 80% of total cellular thioesterase activity, demonstrating that PTE1 is the major long-chain acyl-CoA thioesterase in yeast grown on oleate. Furthermore, this deletion impaired growth on oleate, suggesting that efficient beta -oxidation in yeast requires the expression of this thioesterase, possibly to closely regulate the intraperoxisomal CoASH levels. Our data now suggest that PTE-2 is in fact a major acyl-CoA thioesterase, which can hydrolyze a wide variety of CoA esters in peroxisomes also in the mouse. The difference in acyl-CoA chain length specificity of PTE-2 in our study compared with previous studies is due to the inclusion of albumin to the thioesterase assay when measuring activity with acyl-CoAs longer than decanoyl-CoA. With addition of albumin, it became evident that PTE-2 hydrolyzes all acyl-CoAs of two carbons up to twenty carbons with very similar Vmax. The inhibition of PTE-2 activity by CoASH indicates that this enzyme can "sense" intraperoxisomal CoASH levels, and thus when there is a requirement for CoASH, PTE-2 is active, whereas during times of high free CoASH, PTE-2 can be inhibited. Peroxisomes contain a distinct pool of CoASH (43, 44), which has been reported to change during fasting and treatment with peroxisome proliferators (45). The extent of CoASH sequestration may therefore depend on the size of the CoASH pool, the amount and type of lipids being trapped in the beta -oxidation systems in the peroxisome, as well as activities of acyl-CoA thioesterases and possibly a recently cloned peroxisomal nudix hydrolase, which apparently can hydrolyze CoASH to yield 3',5'-ADP and the corresponding 4'-phosphopantetheine derivative (46).

PTE-2 Can Have a Multitude of Functions in Regulating Peroxisomal Lipid Metabolism-- In the present study we have cloned and characterized the mouse PTE-2 with respect to regulation of expression and kinetic activity. Recombinant PTE-2 hydrolyzed all tested CoA esters, showing an almost complete lack of substrate specificity with respect to the carboxylic acid moiety. The enzyme catalyzes the hydrolysis of straight-chain, saturated and unsaturated acyl-CoAs of 2-20 carbons in chain length with roughly similar Vmax. The enzyme also hydrolyzed other CoA esters such as acetoacetyl-CoA, malonyl-CoA, HMG-CoA, clofibroyl-CoA, THCA-CoA and CoA esters of bile acids, and beta -oxidation intermediates. This apparent lack of substrate specificity suggests that the binding site of the enzyme is rather nonspecific with respect to the acyl moiety and that the enzyme may recognize the CoASH moiety for binding. This is in line with the observed inhibitory effect of free CoASH, the kinetics of which suggested a competitive mode of action, although the data were not fully conclusive. Notably, all the CoA esters tested as substrates for PTE-2 can be expected to be present in peroxisomes as substrates, intermediates, or end products in lipid metabolism. In combination with the strong regulation of expression via PPARalpha , the PTE-2 thioesterase may have a multitude of functions in peroxisomes as outlined in Fig. 8. Fatty acids and other substrates for beta -oxidation in peroxisomes must first be esterified to their CoA ester. CoASH that is appended to poorly oxidizable substrates may cause a trapping of CoASH and thereby prevent the beta -oxidation cycle to continue. Thus, PTE-2 may temporarily hydrolyze substrates for the beta -oxidation to release CoASH. We also tested CoA esters of beta -oxidation intermediates, 2-trans-decenoyl-CoA and 3-hydroxypalmitoyl-CoA. Both these CoA esters were poorer substrates compared with the corresponding straight-chain acyl-CoA: 2-trans-decenoyl-CoA was hydrolyzed at a rate of about 22% of that observed with decanoyl-CoA with the Km being increased 6-fold and Vmax being decreased, and 3-hydroxypalmitoyl-CoA, which was hydrolyzed at a rate of about 18% of the rate of hydrolysis of palmitoyl-CoA, with the Km being similar but Vmax being much lower. The lower activities of PTE-2 with beta -oxidation intermediates indicates that the thioesterase preferentially removes the CoA esters of substrates and end products, while beta -oxidation intermediates are allowed to be further oxidized.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 8.   Model for putative functions of PTE-2 in peroxisomes. PTE-2 may function as an auxillary enzyme in beta -oxidation of a number of substrates in peroxisomes. The abbreviations used are: VLCFA, very long-chain fatty acids: CAT, carnitine acetyltransferase; COT, carnitine octanoyltransferase; PG, prostaglandins: LT, leukotrienes; Tb, thromboxanes; FFA, free fatty acid; Cn, carnitine.

However, a number of carboxylic acids, such as prostaglandins, leukotrienes, and thromboxanes are chain-shortened in peroxisomes and excreted in the urine as the free acids, thus requiring an acyl-CoA thioesterase for these processes. The finding in the present study that PTE-2 readily hydrolyzes the CoA ester of prostaglandin F2alpha is the first demonstration of an acyl-CoA thioesterase that can have this function.

In the beta -oxidation of pristanic acid, the intermediate 4,8-dimethylnonanoyl-CoA (DMN) is formed and is transported from the peroxisome to the mitochondria as a carnitine ester, for further oxidation. The high activity of recombinant PTE-2 toward DMN-CoA indicates that PTE-2 may also be able to hydrolyze DMN-CoA to DMN and release CoASH for other beta -oxidation reactions in peroxisomes if required. The DMN could then be re-esterified to CoASH by the very long-chain acyl-CoA synthetase in peroxisomes (47).

PTE-2 Is a PPARalpha Target Gene That May Regulate Bile Acid Formation-- Bile acids are formed in liver peroxisomes by beta -oxidative cleavage of the side chain of DHCA-CoA or THCA-CoA to chenodeoxycholoyl-CoA and choloyl-CoA, respectively, with the concomitant production of propionyl-CoA. In the last step, bile acid-CoAs are conjugated to taurine or glycine, a reaction catalyzed by the BAAT enzyme that acts as an acyltransferase. In fact the best substrates for PTE-2 were found to be THCA-CoA, CA-CoA, and CDCA-CoA. We have now established that PTE-2 is the bile acid-CoA thioesterase identified previously (19, 20), suggesting that a major function of the PTE-2 in liver may be in regulation of bile acid formation and excretion. This conclusion is further supported by the competition experiment carried out, which showed that addition of a small amount of recombinant PTE-2 to peroxisomes severely suppresses the activity of BAAT, presumably due to consumption of the substrate CDCA-CoA. PPARalpha has been established as a key regulator of lipid metabolism, but was also shown to be involved in regulation of bile acid metabolism (38), thus connecting the pathways of bile acid and fatty acid metabolism. Up-regulation of PTE-2 by WY-14,643, together with the PTE-2-mediated suppression of bile acid conjugation with taurine in vitro, could imply that PPARalpha is also involved in regulating bile acid amidation. Indeed, preliminary data show a reduction in conjugated bile acids in mouse liver following treatment with WY-14,643.3 This functional aspect may be very important in view of the recent interest in the farnesoid-X-receptor (FXR), a nuclear receptor that acts as a biological sensor for the regulation of bile acid biosynthesis, and that is activated by free and conjugated chenodeoxycholic acid (48, 49) and cholic acid (50). The FXR/RXR regulates expression of genes involved in bile acid metabolism, such as the human ileal bile acid-binding protein (51) and cholesterol 7alpha -hydroxylase (52, 53). Increased PTE-2 activity would therefore result in an increase in free bile acids, which may subsequently be transported to the nucleus to activate the FXR/RXR heterodimer complex. In this way, PTE-2 may mediate cross-talk between the PPARalpha and the FXR signaling pathways.

With the identification of the gene for the human PTE-2, a putative peroxisome proliferator-response element was identified at 438 bp upstream of the ATG start site. This site conforms well to the consensus direct repeat 1 (AGGTCAnAGGTCA), which has been shown to bind both PPAR/RXR heterodimers and hepatocyte nuclear factor 4alpha . It will be of interest to identify if this site is functional in the human promoter in binding these transcription factors, thus leading to possible activation of human PTE-2 by either peroxisome proliferators or fatty acids (the ligands for PPARs (3, 4)), or acyl-CoAs and CoA esters of peroxisome proliferators (the agonists/antagonists for hepatocyte nuclear factor 4alpha (54, 55)).

Can PTE-2 Be Considered as an Auxilliary beta -Oxidation Enzyme?-- In addition to bile acid intermediates, PTE-2 efficiently hydrolyzes methyl-branched fatty acids (e.g. 4,8-dimethylnonanoyl-CoA and 2-methylstearoyl-CoA), which are substrates of the "branched-chain" beta -oxidation pathway in peroxisomes. Branched-chain CoA esters appear to be excellent substrates for PTE-2, but are generally slowly metabolized via beta -oxidation in peroxisomes. At first sight, there appears to be a paradoxical situation that an acyl-CoA thioesterase should facilitate degradation of lipids. However, as outlined before, it is probably very important that appropriate CoASH levels are maintained in peroxisomes. Such a function is supported by the findings in yeast that deletetion of the gene encoding the yeast homologue PTE1 impairs growth of the PTE1 knock-out strain on oleate. Therefore, a possible function of PTE-2 may be to act as an auxilliary enzyme in beta -oxidation of branched-chain fatty acids/bile acid formation. This beta -oxidation pathway is not PPARalpha -regulated, and therefore the PPARalpha -mediated up-regulation of PTE-2 may function in salvaging CoASH for beta -oxidation of fatty acids or alternatively function in (temporarily) decreasing beta -oxidation of branched-chain lipids. This could serve to mediate a metabolic cross-talk between PPARalpha and degradation of this class of lipids in the liver. It should be stressed that it is very likely that PTE-2 can play different functions in different organs which could be related to organ-specific metabolic function of peroxisomes in different tissues.

Is PTE-2 Involved in Regulation of Cholesterol Synthesis in Peroxisomes?-- As outlined above, the PPARalpha regulation of PTE-2 may confer a metabolic crosstalk between fatty acid degradation and cholesterol metabolism. A similar metabolic cross-talk may occur by PPARalpha regulation of PTE-2 activity, which may interefere with peroxisomal cholesterol biosynthesis. The initial enzymes involved in cholesterol synthesis have been demonstrated to be present in peroxisomes. These enzymes include acetoacetyl-CoA thiolase (56), HMG-CoA synthase (57), and HMG-CoA reductase (58, 59). PTE-2 hydrolyzes acetyl-CoA (substrate for acetoacetyl-CoA thiolase), acetoacetyl-CoA (substrate for HMG-CoA synthase), and HMG-CoA (substrate for the HMG-CoA reductase). In addition, while the peroxisomal HMG-CoA reductase is up-regulated 2 h into the light cycle (60), PTE-2 is most highly expressed at the end of the light cycle/beginning of the dark cycle, indicating a functionally coordinated regulation of expression, i.e. high expression of PTE-2 when HMG-CoA reductase is expressed at low levels.

Role of PTE-2 in Regulation of Short-chain Acyl-CoAs Generated from Peroxisomal beta -Oxidation-- beta -Oxidation of straight-chain and branched-chain fatty acids produces chain-shortened acyl-CoAs, which may be transferred to mitochondria (as carnitine esters) for further metabolism or be excreted in urine. However, for each cycle in the beta -oxidation, acetyl-CoA and propionyl-CoA are also produced. Accumulation of propionyl-CoA can be associated with impaired metabolism (61). Propionyl-CoA is formed from the beta -oxidation of pristanoyl-CoA and other branched-chain acyl-CoAs and bile acid intermediates in peroxisomes. This propionyl-CoA may be transferred to carnitine by peroxisomal carnitine acetyltransferase for further metabolism in mitochondria or hydrolyzed to propionic acid. Propionyl-CoA thioesterase activity has previously been identified in peroxisomes (23, 24). Our present data show that PTE-2 can efficiently hydrolyze propionyl-CoA with a Km of <10 µM and a Vmax of about 3.45 µmol/min/mg of protein. Therefore PTE-2 could prevent accumulation of propionyl-CoA and thus release free CoASH for other reactions. In a similar manner, acetyl-CoA units are released during beta -oxidation of both very long- and long-chain acyl-CoAs and dicarboxylic acids and are then transferred to carnitine by carnitine acetyltransferase for further metabolism in mitochondria or hydrolyzed to acetate and excreted to cytosol. Free acetate can account for total acetyl-CoA produced in peroxisomes from dicarboxylic and monocarboxylic acids, and acetate production is increased by peroxisome proliferator treatment (62). The production of free acetate from acetyl-CoA requires the hydrolysis by an acyl-CoA thioesterase present in peroxisomes (23, 24). Again, recombinant PTE-2 showed high activity toward acetyl-CoA, which constitutes a mechanism to prevent trapping of CoASH in the acetyl-CoA unit.

In summary, we have shown that PTE-2 acts as a general acyl-CoA thioesterase that is responsible for most of the thioesterase activity detected in isolated peroxisomes. Furthermore, PTE-2 is highly regulated by WY-14,643 and fasting, which identifies PTE-2 as a novel PPARalpha target gene. Based on the regulation of expression and regulation of enzymatic activity by CoASH levels, it is likely that PTE-2 has important functions in regulating peroxisomal lipid metabolism. We therefore propose that PTE-2 is a major thioesterase found in peroxisomes that may regulate intracellular peroxisomal CoASH levels, controlling beta -oxidation of a broad range of acyl-CoA metabolites and the levels of free and conjugated bile acids in liver. PTE-2 could also be a candidate gene for some of the hitherto unidentified disorders of peroxisomal fatty acid metabolism. Targeted disruption of the gene for PTE-2 should provide an interesting model to examine the role of this enzyme in many of the diverse metabolic pathways in peroxisomes.

    ACKNOWLEDGEMENTS

We thank Frank Gonzalez and Jeffrey Peters for PPARalpha -null mice, Jacob Jones for PTE1 antibody, Jan Pedersen for THCA-CoA and 2-methylstearoyl-CoA, Ronald Wanders for 4,8-dimethylnonanoyl-CoA, Kilervo Hiltunen for 2-trans-decenoyl-CoA, Nikolaos Venizelos for 3-hydroxypalmitoyl-CoA, Manfred Held for synthesis of the prostaglandin F2alpha -CoA ester, and Kjell Hultenby for GFP antibody. We also gratefully acknowledge the advice and assistance of Cecilia Rustum and Einar Hallberg regarding GFP experiments and for the GFP secondary antibody.

    FOOTNOTES

* This work was supported by the Swedish Society for Medical Research, the Swedish Medical Research Council, the Swedish Natural Science Research Council, Hjärt-Lungfonden, and Amersham Biosciences, Inc.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF441166.

Dagger To whom correspondence should be addressed: Dept. of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry C1-74, Karolinska Institutet, Huddinge University Hospital, SE-141 86 Stockholm, Sweden. Tel.: 46-8-58581293; Fax: 46-8-58581260; E-mail: mary.hunt@chemlab.hs.sll.se.

§ Present address: Inst. for Nutrition Research, University of Oslo, NO-0316 Oslo, Norway.

Published, JBC Papers in Press, October 22, 2001, DOI 10.1074/jbc.M106458200

2 M. C. Hunt, A. Rautanen, T. L. T. Svensson, and S. E. H. Alexson, manuscript in preparation.

3 K. Solaas, M. C. Hunt, V. Pham, G. Alvelius, K. Hultenby, B. F. Kase, and S. E. H. Alexson, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: PPARalpha , peroxisome proliferator-activated receptor alpha ; CoA, coenzyme A; PTE-2, peroxisomal acyl-CoA thioesterase-2; CoASH, coenzyme A, reduced; THCA-CoA, trihydroxycoprostanoyl-CoA; DHCA, dihydroxycoprostanoyl-CoA; CA-CoA, choloyl-CoA; CDCA-CoA, chenodeoxycholoyl-CoA; DMN-CoA, 4,8-di-methylnonanoyl-CoA; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; BAAT, bile acid-CoA:amino acid N-acyltransferase; FXR, farnesoid-X-receptor; RXR, retinoid-X-receptor; BSA, bovine serum albumin; PBS, phosphate-buffered saline; HPLC, high-pressure liquid chromatography; GFP, green fluorescent protein; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); Tritc, tetramethylrhodamine-5-isothiocyanate; HIV, human immunodeficiency virus.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Van Veldhoven, P. P., and Mannaerts, G. P. (1999) Adv. Exp. Med. Biol. 466, 261-272
2. Reddy, J. K., and Hashimoto, T. (2001) Annu. Rev. Nutr. 21, 193-230
3. Forman, B. M., Chen, J., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317
4. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and Lehmann, J. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4318-4323
5. Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995) Mol. Cell. Biol. 15, 3012-3022
6. Aoyama, T., Peters, J. M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T., and Gonzalez, F. J. (1998) J. Biol. Chem. 273, 5678-5684
7. Hunt, M. C., Lindquist, P. J. G., Peters, J. M., Gonzalez, F. J., Diczfalusy, U., and Alexson, S. E. H. (2000) J. Lipid Res. 41, 814-823
8. Kroetz, D. L., Yook, P., Costet, P., Bianchi, P., and Pineau, Y. (1998) J. Biol. Chem. 273, 31581-31589
9. Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., and Wahli, W. (1999) J. Clin. Invest. 103, 1489-1498
10. Leone, T. C., Weinheimer, C. J., and Kelly, D. P. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7473-7478
11. Lewin, T. M., Kim, J. H., Granger, D. A., Vance, J. E., and Coleman, R. A. (2001) J. Biol. Chem. 276, 24674-24679
12. Gargiulo, C. E., Stuhlsatz-Krouper, S. M., and Schaffer, J. E. (1999) J. Lipid Res. 40, 881-892
13. Yamada, J., Itoh, S., Horie, S., Watanabe, T., and Suga, T. (1986) Biochem. Pharmacol. 35, 4363-4368
14. Yamada, J., Ogawa, S., Horie, S., Watanabe, T., and Suga, T. (1987) Biochim. Biophys. Acta 921, 292-301
15. Diczfalusy, U. (1994) Prog. Lipid Res. 33, 403-428
16. Hunt, M. C., and Alexson, S. E. H. (2001) Prog. Lipid Res., in press
17. Pedersen, J. I., and Gustafsson, J. (1980) FEBS Lett. 121, 345-348
18. Kase, F., Björkhem, I., and Pedersen, J. I. (1983) J. Lipid Res. 24, 1560-1567
19. Solaas, K., Ulvestad, A., Söreide, O., and Kase, B. F. (2000) J. Lipid Res. 41, 1154-1162
20. Solaas, K., Sletta, R. J., Søreide, O., and Kase, B. F. (2000) Scand. J. Clin. Invest. 60, 91-102
21. Osmundsen, H., Neat, C. E., and Borrebaek, B. (1980) Int. J. Biochem. 12, 625-630
22. Berge, R. K., Flatmark, T., and Osmundsen, H. (1984) Eur. J. Biochem. 141, 637-644
23. Alexson, S. E. H., Osmundsen, H., and Berge, R. K. (1989) Biochem. J. 262, 41-46
24. Wilcke, M., and Alexson, S. E. H. (1994) Eur. J. Biochem. 222, 803-811
25. Hunt, M. C., Nousiainen, S. E. B., Huttunen, M. K., Orii, K., Svensson, L. T., and Alexson, S. E. H. (1999) J. Biol. Chem. 274, 34317-34326
26. Jones,